The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000032393
Abstract: Background: Nivolumab is the human programmed cell death-1 (PD-1)-blocking antibody showing significant effect in many refractory cancers. However, little is known about its risks of hematological toxicities, rare but clinically serious and potentially life-threatening adverse… read more here.
Keywords: hematological toxicities; meta analysis; neutropenia leukopenia; anemia neutropenia ... See more keywords